AC
Applied Clinical Trials
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
0:00-1:47
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
Publisher
Applied Clinical Trials
Link
audioboom.com/posts/8974352
Published
November 9, 2026
Duration
2 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
AC
Applied Clinical Trials
@appliedclinicaltrials
#apacinspectionfindings #rbqmkeyrisk #neckcancerapproval #lifesciences
